Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mcmartin:
"Is anyone able to recall the amount of shares the Gabriels and Gomez own of Biofrontera? Thanx ia."
http://www.sys-con.com/node/292805
I don't know whether it's still in activity or doa.
Take care,
Ann
The Genetic Alliance’s Terry said that Obama “has surrounded himself with Nobel Laureates and seasoned domain experts to advise the campaign,” and she called the emphasis on science as a primary domestic agenda “unprecedented.” Genetic Alliance views the campaign’s specific set of advisors as representatives of “a tipping point” for genetics and genomics in public policy, she added.
The president-elect also introduced last year a genomics and personalized medicine bill that, in its 2008 form, would promote genomics and pharmacogenomics studies in government, offer tax credit incentives for genomics research, would start a biobanking initiative, and would aim to develop some oversight for genetic testing.
This bill expired last year and was re-introduced this year by Representative Patrick Kennedy (D – RI) and will be a priority, Hughes said at a meeting on Capitol Hill in July with the Genetic Alliance.
Hughes also said at that meeting that some parts of the bill could be done through other channels if Obama were to win the White House. Terry thinks that the new president could use the executive order privilege “to make things happen quickly and to enforce a sound public approach that could have a profound impact.”
The Kennedy bill would create a Genomics and Personalized Medicine Interagency Working Group that would include the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, and other groups outside of the Department of Health and Human Services.
The National Biobanking Initiative would create a database for collecting and integrating genomics and environmental health data and information. Another section would use funding to improve diagnosis of genetic diseases, and for treatment and counseling. Rep. Kennedy also has added a tax credit for research expenses incurred in the development of a companion diagnostic test.
“As the bill identifies, incentives are necessary for us to realize the potential of personalized medicine,” PMC’s Miller explained. Miller also said that two other ideas PMC has proposed are in one version of the act, including a tax credit for R&D costs and “a streamlined process through FDA for drug-diagnostic tests for pharmaceuticals.”
The bill also proposes using a matrix of oversight for regulating genetic and pharmacogenomic tests, which Terry calls “a mindful approach” that is aware “of the need not to over-regulate this emerging technology.”
“Obama has been one of the foremost leaders in considering genomics and personalized medicine, and this is a great opportunity to work with an administration that’s aware of these issues,” BIO’s Pritchard added.
As an example, Pritchard said, “The genomics bill has specific provisions, and that’s why we can have this conversation about what can be enacted, legislative or executive.”
The Obama administration also is expected to continue the Personalized Health Care initiative that was started by current Department of Health and Human Services Secretary Michael Leavitt. That program aims to link clinical and genomic information, support genetic information discrimination law, ensure accuracy and validity of genetic tests, and develop common policies for access to genomic databases.
Terry told GWDN that the Obama campaign said it expected to continue the PHC initiative at least beyond the beginning of 2009, and that Genetic Alliance hopes that the new administration will “bring discipline and focus to the program” and will be able to effect real change that makes a difference in real health outcomes.
“Personalized medicine could become a catch phrase that becomes a parking lot for hype,” Terry warned. “It is essential it is grounded in the needs of real patients and real healthcare providers – it is transformative, but only when it is also practical and accessible,” she said.
Take care,
Ann
(cont'd.)
How much funding NIH receives is only part of the issue. How that money is used also is an important consideration.
“The rising cost of healthcare will be one of Obama’s many challenges and personalized medicine is a bold new approach to improving healthcare while lowering costs; Obama understands this,” Personalized Medicine Coalition Public Policy Director Amy Miller told GWDN in an e-mail.
More...
Ann
The funding question, particularly for the National Institutes of Health, will be the most pressing. President-elect Obama will arrive to the Oval Office in the midst of a financial crisis, and will be confronted with a 2009 federal budget that has yet to be agreed upon.
NIH "has been historically challenged, regardless of the funding amounts, with doing more than just basic biomedical research,” Genetic Alliance President and CEO Sharon Terry told GenomeWeb Daily News on Thursday.
Terry also thinks that the Chicago politician’s “integrated vision for a modern, evidence-based and effective health care delivery system … can only mean positive things for personalized medicine products and services.”
More...
Ann
A tremendous amount of luck to you, Dan! (and all included - lol)
Genome Web Daily news Headline today,11/7: "Personalized Medicine Policy Advocates Have High Hopes for New President"
This is a registrant site, but, I will post highlights/blurbs from article later this p.m., if the board wishes, since I don't get home till late.
Take care,
Ann
dgplexus:
Just to let you know I,for one,appreciate your attitude!
Take care,
Ann
What's the date, Sam?
Ann
Complete list traded on Xetra:
DNAP in there. What are other opinions out there?
http://deutsche-boerse.com/dbag/dispatch/en/xetraInstruments/gdb_navigation/trading/20_tradable_instruments/900_tradable_instruments/100_xetra?selectedKey=D&grp=&type=
Ann
DNAP listed on Deutche Borst Group, Xetra, German Stock Exchange:
http://deutsche-boerse.com/dbag/dispatch/en/xetraInstruments/gdb_navigation/trading/20_tradable_instruments/900_tradable_instruments/100_xetra?isin=US23324Q2021&grp=&type=
Ann
Biofrontera is still only affiliate on DNAP website:
http://www.dnaprint.com/welcome/subsidiaries/
Ann
Ancestry by DNA Products & Services:
http://www.ancestrybydna.com/welcome/productsandservices/
Seems to still be breathing?
Ann
Late - sorry
Though it didn't show up as I hoped it would post - 9/19 is the date - anyone want confirmation - I will retrive it as a reference, otherwise, it's confirmation.
Ann
DNAG removed from Sho 9/19:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=dnag
Ann
Didn't forget, Sam - 'accidentally' picked wrong first letter for phonetics.
Take care,
Ann
Whoops - "Spaseeba!"
lol
Ann
Sam:
Are "all" the distributor links you list actually DNAP-related?
Just curious.
Take care,
Ann
From YouTube:
I wonder at what point the public will finally retaliate and
come to the realization that we, the American public, are being mistreated by the medical profession in an extremely disingenious way much to the interest of Big Pharma.
So many foreign doctors also have been allowed to practice medicine in this great country of ours, who take advantage of the true code of ethics that this country was built on, our American know-how, expertise and professionalism.
So many drs. are cheating the public and taking advantage of our system on a a daily basis, using our people and citizens as guineia pigs and making us reliant on their false and misleading diagnosis, unprofessional unneeded and unwarranted medical screenings & misdiagnosis, most often to the benefit of their financial gains. At what point is the public ultimately going to fight back?
It's obvious that we're at most drs. mercy - but, again, many foreign drs. planted as practisioners in this great country of ours, plus Big Pharma, are controlling us and their needs by cheating the public since there doesn't seem to be a watchdog. They are getting rich at our expense, our health and our lives!
JMHO
David:
"Good to see you are still interested and posting"
(Looks like my "home away from home" at least for the time being - lol)
It's good to see you still here also, David.
Take care,
Ann
Why is Biofrontera still listed on DNAP website as the only subsidiary and affiliate?
http://dnaprint.com/welcome/subsidiaries/
Ann
"Dear Patrons,
You may have seen the press release announcing the merger of ReliaGene Technologies, Inc. and Orchid Cellmark, Inc. We are very excited about the alliance, but we know your initial question will probably be �how will this affect me?� Rest assured that we intend to continue to provide you with the level of service you have come to expect from ReliaGene. We want this change to be as seamless and transparent as possible, meaning our laboratory operations, customer services and reporting will be unchanged in the near term.
Orchid is the oldest and most experienced company in the human identity testing field and services clients in both the forensic and paternity markets. Their U.K. lab, in addition to human identity testing, also serves the agricultural community with testing for selective trait breeding. Orchid has four labs in the U.S.- two forensic and two paternity, and employs a highly experienced and respected scientific staff. Orchid scientists have testified in over 2000 cases in all fifty states.
We believe this merger of two of the largest and most experienced DNA labs in the country will enable us to provide you with unparalleled service and will give us the resources to meet your growing needs. As we integrate our two companies, we will welcome your comments to let us know how we are doing.
Thank you for your ongoing support.
Sincerely,
Sudhir K. Sinha, Ph.D.
President and Laboratory Director
ReliaGene Technologies, Inc."
Ann
Frog:
http://www.reliagene.com/ (a merger)
Ann
Late hr. here - To a better tomorrow!
Ann
A sample of an article posted:
DNA Direct Replies to Science: A Case Study of Personalized Medicine
April 4th, 2008 by Lisa Lee
Yet again, I’m frustrated by people confusing web access to genetic services with “direct-to-consumer” testing. Today in Science, Katsanis et al. lump DNA Direct’s gold standard services with what journalists at Newsweek are calling “snake oil.”
Contrary to the article published in Science that is being quoted in other news sources, DNA Direct is a healthcare provider just like any bricks-and-mortar genetics center. We provide medical genetic services according to evidence-based guidelines, under the oversight of a Medical Director who is an M.D. geneticist, and with a focus on proper interpretation of test results.
As a clinical provider committed to helping consumers understand genetic test results in context, it is inaccurate to describe our company as “bypassing doctors, who could help consumers interpret and use the findings.” In fact, we routinely work with physician practices to help both the referring physician and their patient access genetic testing and appropriately interpret the results.
Ann
Sam, et all:
You can get "tons" of information posted on this DNADirect website. I'm turning it over to you to peruse & post all the pertinent information you desire:
http://talk.dnadirect.com/?refLink=dna_footer
Ann
Good luck to you,dgplexus. Dare I include 'us?'
Take care,
Ann
Interesting and maybe helpful for some of you to know:
http://news.aol.com/health/article/fda-posts-list-of-potential-problem/162319?icid=200100397x1208933996x1200528559
Ann Ell
If anyone's interested re: Merck
http://money.aol.com/investing/companies-to-lay-off-10000-this-year?icid=200100397x1209143411x1200511651
Ann
Sam:
I'm glad you reposted to show a more recent date of update on website.
The one you originally posted had '07 as the last date, leading one to believe it was old news. But, you corrected that.
Take care,
Ann
Refer to bottom of page:
http://www.dnadirect.com/patients/tests/genealogy_testing/selecting_our_preferred_providers.jsp
Ann
Sam:
DNA Direct website:
this page last updated: October 15, 2007
Ann
"DNAPrint is a DNA Direct preferred provider for autosomal ethnicity testing. DNAPrint offers the AncestryByDNA 2.5, EurasianDNA 1.0, and EuroDNA 2.0 tests that use innovative, cutting-edge technology to examine single nucleotide polymorphisms (SNPs) ancestry informative markers along all 22 non-sex chromosomes. These ancestry tests can be used to determine the anthropological origins of an individual's ancestry."
Ann
One affiliate left on DNAP website:
Subsidiaries and affiliates
http://www.biofrontera.com
Biofrontera AG is establishing a specialty pharmaceutical business for research and development in dermatology and inflammation. The company’s state-of-the-art laboratory facilities in Leverkusen, Germany, are modern and fully-equipped with sufficient space for projected growth and market expansion.
Biofrontera’s specific expertise lies in the characterization of the pharmacological properties of drug candidates in vitro and in vivo. Biofrontera’s goal is to build a specialty pharmaceutical company with wholly owned products, initially for dermatologic applications. In the future, other pharmaceuticals for larger markets will result from Biofrontera’s in-house research.
In addition, Biofrontera AG holds a wholly-owned subsidiary, Biofrontera Pharmaceuticals GmbH. Biofrontera Pharmaceuticals GmbH has three drugs in pre-clinical and clinical development. Two drugs are in phase II trials; the leading compound is expected to enter the market in 2007/08. Click here to get the latest Biofrontera Bond update.
Ann
Some info from DNAP website:
http://www.dnaprint.com/welcome/corporate/
Ann
Does anyone know if we're still involved in the Biofrontera Bond or IPO into the Euro Market?
Ann
uca:
"The only connection w/DNAPrint as of today on their website is Biofrontera???"
Sorry to have been so vague. It was late (my time).
If you go to DNAPrint.com and look under Subsidiaries, you will see that Biofrontera is the only one that remains. Though, Trace is listed, it has not yet been removed, although it is now unaccessable.
Take care,
Ann
Uccaducca:
The only connection w/DNAPrint as of today on their website is Biofrontera???
Ann
mbmun:
"did you find out what your broker meant by DNAPrint Genomics
NEW."
Talked to a rep & then a broker at Chas. Schwabb and neither one knew what the significance of NEW meant on my statements. If these two top sources didn't know...I don't know...who WOULD know.
Take care,
Ann
mbmun:
"did you find out what your broker meant by DNAPrint Genomics
NEW."
I think I'll call Schwabb next week and inquire.
Take care,
Ann